Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
Go back to Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 1.11 +0.04 (3.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.07 | 52 Week High | $13.20 | |||
| Open | $1.08 | 52 Week Low | $7.00 | |||
| Day High | $1.14 | P/E | N/A | |||
| Day Low | $1.08 | EPS | $0.00 | |||
| Volume | 2,306,470 | |||||
